Fredun Pharma Peer Comparison

BSE: 539730

₹1,382.60

₹34.40 (2.55%)

As on 22-Sep-2026IST

Market cap

₹2,325 Cr

Revenue (TTM)

₹748 Cr

P/E Ratio

P/B Ratio

7.9

Div. Yield

0 %

Edit

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	2,325	35,504	27,675	26,306	27,978
Revenue (₹ Cr)	748	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	43.82	414.00	288.22	387.35	-371.81
Net Margin (%)	5.86	11.23	14.79	26.01	-3.93
RoE (%)	20.13	8.38	29.77	25.18	-3.85
Price to Earnings	53.05	86.81	96.02	68.11	--
Price-To-Book	7.92	7.05	20.62	15.25	3.50

Income Statement (₹ Cr)

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	747.51	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	747.51	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	636.94	2,792.00	1,485.56	919.25	8,195.15
EBITDA	110.58	772.00	450.24	542.56	1,010.13
Depreciation	10.07	226.00	50.83	37.68	857.51
EBIT	100.51	546.00	399.41	504.88	152.62
Interest	41.38	217.00	40.84	3.77	342.73
Other Income	0.00	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	59.13	463.00	371.35	528.56	-162.68
Provision for Tax	14.69	49.00	83.14	141.21	209.13
Profit after Tax	44.44	414.00	288.22	387.35	-371.81

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	278.71	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	67.11	1,712.00	202.03	42.40	5,044.14
Current Liabilities	296.31	1,622.00	835.87	230.82	4,758.28
Total Liabilities	--	8,578.00	2,326.71	1,983.96	17,723.32

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	120.25	5,343.00	519.60	1,026.85	10,211.52
Current Assets	498.24	2,606.00	1,681.81	881.27	7,191.66
Total Assets	--	8,578.00	2,326.71	1,983.96	17,723.32
Total Debt*	--	2,125.00	259.37	26.49	5,495.48
Net Current Assets	201.93	984.00	845.94	650.46	2,433.38
Contingent Liabilities	--	768.26	19.09	17.25	95.72

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	--	390.00	205.05	292.17	1,652.60
Cash Flow from Investing Activities	--	-241.00	-409.72	-265.94	-826.03
Cash from Financing Activities	--	-54.00	283.07	4.10	-38.98
Net Cash Inflow / Outflow	--	95.00	78.39	30.33	787.59

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	--	6.79	29.22	32.42	1.24
ROE (%)	20.37	8.38	29.77	25.18	-3.85
ROA (%)	7.87	4.94	24.77	21.93	-2.21
EBIT Margin (%)	13.45	15.32	20.63	34.54	1.66
Net Margin (%)	5.94	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	50.31	18.37	46.65	40.90	0.78
EBIT Growth (%)	76.98	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	89.55	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	37.58	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	--	13.47	144.31	26.03	0.33

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	20.24	89.10	94.55	68.11	-89.41
Price / Book Value	7.90	7.05	20.62	15.25	3.50
Dividend Yield (%)	0.02	0.00	0.09	0.08	0.00
EV/EBITDA	22.45	47.88	61.28	48.12	31.80
Market Cap (₹ Cr)	--	19,071.62	12,753.19	20,944.75	18,108.89

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.20	0.31	0.11	0.02	0.53
Short term debt to equity ratio	--	0.09	0.05	0.02	0.09
Current Ratio	1.68	1.61	2.01	3.82	1.51
Quick Ratio	0.77	1.06	1.14	2.82	0.87
Interest Coverage	2.43	3.13	10.09	141.16	0.53

	Fredun Pharma	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	12.40	16.50	26.28	24.80	23.44
Asset Turnover	1.32	0.43	1.66	0.83	0.55
Receivable days	--	58.75	40.13	88.98	78.20
Inventory Days	--	75.82	60.29	56.04	93.30
Payable days	--	186.21	232.47	99.95	226.14
Cash Conversion Cycle	--	-51.64	-132.04	45.07	-54.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.